New Drug Rulings May Confuse Investors
WASHINGTON (Reuters) - A change in how the United States responds to drug applications threatens to add more uncertainty for investors trying to gauge if a new medicine will reach the world's largest pharmaceutical market. The approach could cloud a drug review process already growing less predictable as global pharmaceutical companies find less success winning U.S. approval for new products.